Annoviant announced today that it received a $1.85 million NIH grant to help further the development and commercialization of its TxGuard.
Atlanta-based Annoviant’s latest grant for the TxGuard pulmonary-valved conduit represents a continuation of the Phase I Small Business Technology Transfer (STTR) grant the company received in 2019, according to a news release.
The conduit, tailored primarily toward pediatric patients, offers an option for treating congenital heart disease (CHD) designed to resist early degeneration while allowing regeneration with host cells, enabling the device to grow with children.
Annoviant’s TxGuard “scaffolding” offers clinical advantages over commercial products, the company says. It includes what the company touts as cutting-edge qualities, making it resistant to calcification, thrombosis, and infection It can regenerate and grow with patients, distinguishing it from other options.
“We’re extremely pleased to receive this grant, and we are grateful for the National Heart, Lung, and Blood Institute’s financial support,” Annoviant co-founder & CEO Ajay Houde said in the release. “The grant funding will enable us to address the clinical and cost challenges associated with treating CHD in children.”